Clinical Trials Sponsored by Britannia Pharmaceuticals Ltd

Total 4443 results

Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

Pooled Analysis FP_SX_250_50

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetics of Probucol and Cilostazol

Healthy

Korea, Republic of
Hemay Pharmaceutical PTY. LTD.
Tianjin Hemay Pharmaceutical Co., Ltd

Unknown

PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers

Inflammatory Bowel Disease

Australia
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Tourette's Disorder | Chronic Motor or Vocal Tic Disorder

Korea, Republic of
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Unknown

Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients

Oral Mucositis

Korea, Republic of
Jina Pharmaceuticals Inc.
Lambda Therapeutic Research Ltd.; Intas Pharmaceuticals, Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Triple Negative Breast Cancer

United States, India
Daewoong Pharmaceutical Co. LTD.
Shanghai Haini Pharmaceutical Co., Ltd.

Active, not recruiting

A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects

Phase 1 Study, Healthy Volunteers

China
Ganzhou Hemay Pharmaceutical Co., Ltd
Hemay Pharmaceutical PTY. LTD.

Completed

A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers

Healthy

Australia
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Solid Tumor

Korea, Republic of
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
InnoBM Pharmaceuticals Co., Ltd.

Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors (BM201-1001)

Advanced Solid Tumors

China
Lynk Pharmaceuticals Co., Ltd

Recruiting

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Acne

China
Forward Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.

Metastatic Breast Cancer | Breast Cancer Stage I | Locally Advanced Breast Cancer | ER+ Breast Cancer

China
BioNova Pharmaceuticals (Shanghai) LTD.

Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

AML, Adult | ALL, Adult

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Safety & Efficacy of Genakumab in Patients With Frequent Flares

Acute Gout

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

Adenocarcinoma of Stomach

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

COVID-19 | Healthy

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Solid Tumors | ER+ Breast Cancer | ARID1A Gene Mutation | Triple Negative Breast Cancer, TNBC | Small Cell Lung Cancer, SCLC

United States, China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Metastasis, Neoplasm

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Metastatic Non-Small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Solid Tumors, Adult

United States
Foresee Pharmaceuticals Co., Ltd.

Recruiting

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Fanconi Anemia

United States
TaiwanJ Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART)

Non Small Cell Lung Cancer | Brain Metastases

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

United States
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor

Advanced Solid Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Non-small Cell Lung Cancer

China
Foresee Pharmaceuticals Co., Ltd.

Completed

The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.

Asthma, COPD

Netherlands
Jacobio Pharmaceuticals Co., Ltd.

Completed

Mass Balance Study of [14C]JAB-21822

Mass Balance Study in Healthy Subjects

China
Betta Pharmaceuticals Co., Ltd.

Completed

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Solid Tumor | Non-Small Cell Lung Cancer Metastatic

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Breast Cancer

China
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Brazil
JCR Pharmaceuticals Co., Ltd.

Completed

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Mucopolysaccharidosis I

United States, Brazil, Japan

Clinical Trials Sponsored by Britannia Pharmaceuticals Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations